Joint Clinical Assessment, JCA
Taletrectinib (NSCLC)
Dossier assessment
Indication:
Treatment of ROS1 positive advanced non-small cell lung cancer
Timetable
- 1st quarter, 2026
- Start
- 1st quarter, 2027
- voraussichtlicher Abschluss
Project details
- Project no.
- MP-202534
- Report type
- Joint Clinical Assessment, JCA
- Status
- Commission work started
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
This Joint Clinical Assessment (JCA) is being conducted in cooperation with the Dental and Pharmaceutical Benefits Agency (TLV) Sweden.
Further background information can be found here: European health technology assessment